<DOC>
	<DOC>NCT02283671</DOC>
	<brief_summary>First in human study to assess the tolerability and safety profile of treatment with dendritic cell in patients with multiple sclerosis or neuromyelitis optica.</brief_summary>
	<brief_title>Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neuromyelitis Optica</mesh_term>
	<criteria>patients with Multiple sclerosis or neuromyelitis optica diagnosed more than a year before inclusion Expanded Disability Status Scale between 3.0 and 8.5 all subtypes of multiple sclerosis or Neuromyelitis optica Multiple Sclerosis patients who have previously been offered therapeutic alternatives available in indications and either decline or that after receiving treatment for at least 6 months have had an outbreak or an increase of at least 1 point on the Expanded Disability Status Scale (EDSS) (nonresponders) or who have not tolerated treatment Patients with Neuromyelitis optica (NMO) in stable immunomodulatory treatment in the past 6 months or without treatment because they are not candidates to receive it Corticosteroid treatment in the last 30 days Presence of an outbreak in the last month Inability to perform brain Magnetic resonance imaging (with paramagnetic contrast) Serious systemic diseases, including Hepatitis B virus, Hepatitis C Virus, and Human Immunodeficiency Virus. Uncontrolled hypertension, insulindependent diabetes mellitus, heart disease or kidney failure or severe respiratory Personal history of cancer or family history of known hereditary cancer patient participating in other experimental study in the last 3 months women childbearingaged that do not use effective contraceptive methods pregnant or breastfeeding women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>